Drugs in Dev.
Pharmacology/Toxicology
Phase II

Lead Product(s) : GMDTC
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment
Deal Size : Inapplicable
Deal Type : Inapplicable
The Safety and Efficacy of GMDTC for Injection in Subjects with Elevated Cadmium Levels
Details : GMDTC is a Antibiotic drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Cadmium Poisoning.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 09, 2025
Lead Product(s) : GMDTC
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant
Details : ANEB-001 (selonabant) is a CB1 receptor inhibitor, being evaluated for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding
Anebulo Pharmaceuticals Awarded NIDA Grant for Acute Cannabis-Induced Toxic Effects
Details : The funding aims to support the development of ANEB-001 (selonabant) for the potential use as an emergency treatment of acute cannabis-induced toxicities, including cannabis-induced CNS depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
July 22, 2024
Lead Product(s) : Selonabant
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : National Institutes of Health
Deal Size : $1.9 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Paltusotine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Crinetics Reports Positive Topline Data from Phase 2 of Paltusotine for Carcinoid Syndrome
Details : Crinetics lead product candidate CRN00808 (paltusotine), an SST2 agonist. Currently, it is being evaluated in the Phase II clinical trial studies for the treatment of Carcinoid Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2024
Lead Product(s) : Paltusotine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SYHX1901
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SYHX1901 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : SYHX1901
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Persavita's experimental product is composed of three natural ingredients with known immune modulating properties. The company is gearing up to test this experimental product in Covid-19 patients through a phase 2 clinical study already authorized by Hea...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Therapeutic Plasma Exchange
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
Details : Therapeutic Plasma Exchange is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytokine Release Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : Therapeutic Plasma Exchange
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Itacitinib
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytokine Release Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : Itacitinib
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Probiotic
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of a Probiotic Strain on Aspirin-induced GI Damage.
Details : This is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Aspirin Side Effects.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
July 25, 2017
Lead Product(s) : Probiotic
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : Atlantia Food Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Emeramide
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase II
Sponsor : NBMI Science AB
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication
Details : Emeramide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Mercury Poisoning.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2015
Lead Product(s) : Emeramide
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase II
Sponsor : NBMI Science AB
Deal Size : Inapplicable
Deal Type : Inapplicable
